Dr. Reddy's Laboratories announces the launch of Fulvestrant Injection

• Dr. Reddy's Laboratories announces the launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-dose Syringe in the US Market

Hyderabad, India and Princeton, NJ, USA. September 7, 2020 - Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-dose Syringe, a therapeutic equivalent generic version of Faslodex® (fulvestrant) Injection, 250 mg/5 mL (50 mg/mL),  approved by the U.S. Food and Drug Administration (USFDA). 
 
The Faslodex® brand and generic market had U.S. sales of approximately $­­­­­407 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health*.
 
Dr. Reddy’s Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-dose Syringe is available in a carton containing two 5 mL single-dose prefilled syringes.